Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Study sponsor: Immunic AG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-07Estimated
Enrollment · participants450Estimated
Source updated2024-04-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.